Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| CD19 mAb - 01 | PCC | AutoImmunity,Hematological Malignancy | Blood tumor,Autoimmune disease |
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| PEGylation CD3 + CD19 bsAb | Monospecific antibody | Immunological disease | Immunodeficiencies | IND | Global |
Expression analysis of human CD19 on Raji/Human CD19 Knockout Stable Cell Line by FACS.
Cell surface staining was performed on Raji/Human CD19 Knockout Stable Cell Line using PE-labeled anti-human CD19 antibody. The Raji cells were stained with PE-labeled anti-human CD19 antibody as the positive control cell. The Raji cells were stained with PE-labeled isotype control antibody as the negative control cell.
Flow cytometric analysis of Human peripheral blood lymphocytes staining with FITC-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (Cat. No. CD9-FM7A1) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. FITC signal was used to evaluate the binding activity (QC tested).
Anti-CD19 Antibody, Human IgG1 captured on Protein A Chip can bind Human CD19 (20-291) Protein, His Tag (Cat. No. CD9-H53H4) with an affinity constant of 3.49 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
This web search service is supported by Google Inc.
A-Z
